Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood

Abstract

Background:

Inflammation in neuromyelitis optica (NMO) is triggered by a serum antibody against the aquaporin-4 (AQP4). This process requires antibody penetration of the blood–brain barrier (BBB), but the mechanisms for BBB disruption in NMO remain unknown.

Objective:

We examined whether changes in cerebrospinal fluid (CSF) and serum matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and cytokines are associated with BBB disruption in NMO.

Methods:

The concentrations 9 MMPs, 4 TIMPs, and 14 cytokines were measured by multiplex assay in CSF and serum samples from 29 NMO patients, 29 relapsing-remitting multiple sclerosis (MS) patients, and 27 patients with other neurological disorders. We also performed immunohistochemistry for MMP-2 and TIMP-1 expression in post-mortem brain tissues from NMO patients.

Results:

NMO patients exhibited significantly elevated MMP-2, TIMP-1, interleukin-6, and MMP-2/TIMP-2 ratio in CSF (but not sera) than the other groups. The CSF/serum albumin ratio, an index of BBB permeability, was most strongly correlated with CSF MMP-2 concentration, which in turn correlated with CSF interleukin-6 levels. Immunohistochemistry revealed MMP-2- and TIMP-1-positive cells surrounding vessels in NMO lesions.

Conclusion:

In NMO, increased CSF MMP-2, likely induced by interleukin-6 signaling, may disrupt the BBB and enable serum anti-AQP-4 antibodies migration into the central nervous system (CNS).

Keywords

Neuromyelitis optica blood–brain barrier matrix metalloproteinases tissue inhibitors of metalloproteinases

Get full access to this article

View all access options for this article.

References

Wingerchuk

Lennon

Lucchinetti

. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805–815.

Lennon

Kryzer

Pittock

. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473–477.

Jarius

Paul

Franciotta

. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures. J Neurol Sci 2011; 306: 82–90.

Rosenberg

. Matrix metalloproteinases in neuroinflammation. Glia 2002; 39: 279–291.

Takeshita

Ransohoff

. Inflammatory cell trafficking across the blood-brain barrier: Chemokine regulation and in vitro models. Immunol Rev 2012; 248: 228–239.

Ravanti

Kähäri

. Matrix metalloproteinases in wound repair (review). Int J Mol Med 2000; 6: 391–407.

Rubin

Staddon

. The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999; 22: 11–28.

Vandooren

Van Damme

Opdenakker

. On the structure and functions of gelatinase B/matrix metalloproteinase-9 in neuroinflammation. Prog Brain Res 2014; 214: 193–206.

Opdenakker

Nelissen

Van Damme

. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2003; 2: 747–756.

10.

Kossakowska

Edwards

Prusinkiewicz

. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin’s lymphomas. Blood 1999; 94: 2080–2089.

11.

Mano

Shibata

Sumigama

. Tocilizumab inhibits interleukin-6-mediated matrix metalloproteinase-2 and -9 secretions from human amnion cells in preterm premature rupture of membranes. Gynecol Obstet Invest 2009; 68: 145–153.

12.

Song

Korpos

. Focal MMP-2 and MMP-9 activity at the blood-brain barrier promotes chemokine-induced leukocyte migration. Cell Rep 2015; 10: 1040–1054.

13.

Lee

Palace

Stabler

. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999; 122: 191–197.

14.

Waubant

. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers 2006; 22: 235–244.

15.

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

16.

Wingerchuk

Lennon

Pittock

. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485–1489.

17.

Wingerchuk

Banwell

Bennett

. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177–189.

18.

Kurtzke

. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

19.

Hayakawa

Mori

Okuta

. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 2008; 196: 181–187.

20.

Paty

Oger

Kastrukoff

. MRI in the diagnosis of MS: A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38: 180–185.

21.

Hosokawa

Nakajima

Doi

. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: Implication of disruption of blood-brain barrier. J Neuroimmunol 2011; 236: 81–86.

22.

Tasaki

Shimizu

Sano

. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2014; 85: 419–430.

23.

Thanabalasundaram

Pieper

Lischper

. Regulation of the blood-brain barrier integrity by pericytes via matrix metalloproteinases mediated activation of vascular endothelial growth factor in vitro. Brain Res 2010; 1347: 1–10.

24.

Pieper

Pieloch

Galla

. Pericytes support neutrophil transmigration via interleukin-8 across a porcine co-culture model of the blood-brain barrier. Brain Res 2013; 1524: 1–11.

25.

Uzawa

Mori

Arai

. Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6. Mult Scler 2010; 16: 1443–1452.

26.

Silacci

Dayer

Desgeorges

. Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity. J Biol Chem 1998; 273: 13625–13629.

27.

Waubant

Goodkin

Gee

. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999; 53: 1397–1401.

28.

Baramova

Bajou

Remacle

. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997; 405: 157–162.

29.

Arenas

Lopez-Jaramillo

. Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol 2004; 286: C779–C784.

30.

Yeh

. Hypoxia-induced matrix metalloproteinase-13 expression in astrocytes enhances permeability of brain endothelial cells. J Cell Physiol 2009; 220(1): 163–173.

31.

Kostic

Dzopalic

Zivanovic

. IL-17 and glutamate excitotoxicity in the pathogenesis of multiple sclerosis. Scand J Immunol 2014; 79: 181–186.

32.

Ishizu

Osoegawa

Mei

. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005; 128: 988–1002.

33.

Uzawa

Mori

Masuda

. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. Arch Neurol 2011; 68: 913–917.

34.

Uzawa

Mori

Masuda

. CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2013; 84: 517–522.

Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood–brain barrier disruption

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References